The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients

[1] Apperley JF(2009)Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START-A trial J Clin Oncol 27 3472-3479

[2] Cortes JE(2009)Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 114 5426-5435

[3] Kim DW(2008)Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate Clin Cancer Res 14 352-359

[4] Branford S(2005)Comparative analysis of two clinically active BCR–ABL kinase inhibitors reveals the role of conformation-specific binding in resistance Proc Natl Acad Sci USA 102 3395-3400

[5] Melo JV(2008)Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer Br J Cancer 99 1074-1082

[6] Hughes TP(2007)Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis Blood 109 3207-3213

[7] Brave M(2007)Dynamics of BCR–ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors Blood 110 4005-4011

[8] Goodman V(2008)Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase Leukemia 22 2176-2183

[9] Kaminskas E(2010)Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia J Clin Oncol 28 398-404

[10] Burgess MR(2006)2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor J Med Chem 49 6819-6832

[1] Apperley JF(2009)Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START-A trial J Clin Oncol 27 3472-3479

[2] Cortes JE(2009)Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 114 5426-5435

[3] Kim DW(2008)Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate Clin Cancer Res 14 352-359

[4] Branford S(2005)Comparative analysis of two clinically active BCR–ABL kinase inhibitors reveals the role of conformation-specific binding in resistance Proc Natl Acad Sci USA 102 3395-3400

[5] Melo JV(2008)Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer Br J Cancer 99 1074-1082

[6] Hughes TP(2007)Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis Blood 109 3207-3213

[7] Brave M(2007)Dynamics of BCR–ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors Blood 110 4005-4011

[8] Goodman V(2008)Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase Leukemia 22 2176-2183

[9] Kaminskas E(2010)Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia J Clin Oncol 28 398-404

[10] Burgess MR(2006)2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor J Med Chem 49 6819-6832